fda declares semaglutide shortage resolved february 2025 ends as sets deadline for compounders FDA declares semaglutide (Ozempic/Wegovy) shortage

If you live in California and attend your scheduled office/virtual check-ins, the medication can be mailed to you (special shipping, syringes, alcohol pads, and dosing schedule are included.) You will be required to check in every month (in-person or virtual) to review your success, address your concerns, and customize your program

Type: Muscle Growth Factor Analog

Inulin100 mg

An appeal is reasonable when: The medication is covered by your plan but the prior authorization was incomplete or incorrect You meet the BMI and medical criteria but the documentation did not reflect that Required comorbidities exist in your record but were not included in the submission You have documented prior weight-loss attempts that were not submitted The denial appears to be based on missing or misclassified information An appeal is unlikely to succeed when: Your plan completely excludes anti-obesity medications (this is an employer benefit decision, not a clinical one) Your BMI does not meet the plans listed criteria (typically 30+, or 27+ with comorbidities) The required lifestyle program period has not been completed Your plan only covers GLP-1s for diabetes or cardiovascular indications, not weight loss If you are not sure whether your denial is appealable, that is exactly the conversation to have at your medical weight loss visit